FD-IN-1
- Product Name
- FD-IN-1
- CAS No.
- 1646682-14-5
- Chemical Name
- FD-IN-1
- Synonyms
- FD-IN-1;FDIN1,FD IN 1;(S)-2-(2-((3'-(1-amino-2-hydroxyethyl)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)acetic acid;Benzeneacetic acid, 2-[[3'-[(1S)-1-amino-2-hydroxyethyl][1,1'-biphenyl]-3-yl]methoxy]-
- CBNumber
- CB95821386
- Molecular Formula
- C23H23NO4
- Formula Weight
- 377.43
- MOL File
- 1646682-14-5.mol
FD-IN-1 Property
- Boiling point:
- 629.4±55.0 °C(Predicted)
- Density
- 1.251±0.06 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- Soluble in DMSO
- form
- Solid
- pka
- 4.14±0.10(Predicted)
- color
- White to off-white
N-Bromosuccinimide Price
- Product number
- CS-0095901
- Product name
- FD-IN-1
- Packaging
- 25mg
- Price
- $1100
- Updated
- 2021/12/16
- Product number
- CS-0095901
- Product name
- FD-IN-1
- Packaging
- 50mg
- Price
- $1700
- Updated
- 2021/12/16
- Product number
- CS-0095901
- Product name
- FD-IN-1
- Packaging
- 100mg
- Price
- $2500
- Updated
- 2021/12/16
FD-IN-1 Chemical Properties,Usage,Production
Biological Activity
FD-IN-1 (Compound 12) is a potent, orally active complement factor D (FD) inhibitor with IC50 of 12 nM.It also inhibits factor XIa (FXIa) and tryptase β2 with IC50 of 7.7 and 6.5 μM, respectively.
in vitro
FD-IN-1 (Compound 12) exhibits functional inhibition of AP activation (IC 50 =0.26 μM) in vitro in a membrane attack complex (MAC) deposition assay using 50% human whole blood (WB).
in vivo
FD-IN-1 (Compound 12) demonstrates systemic suppression of AP activation in a lipopolysaccharide-induced alternative complement pathway (AP) activation model as well as local ocular suppression in intravitreal injection-induced AP activation model in mice expressing human FD.
FD-IN-1 (Compound 12) exhibits high oral bioavailability (C57BL6 mice 83%, Beagle dogs 70%) following oral administration (mice and dogs 10 mg/kg).
FD -IN-1 (Compound 12) exhibits terminal elimination half-lives (C57BL6 mice 1.6 h and Beagle dogs 3.8 h) following intravenous administration (mice and dogs 1 mg/kg).
b>
| Animal Model: | Human FD knock-in mice |
| Dosage: | 3 and 10 mg/kg |
| Administration: | Oral gavage |
| Result: | The AP pathway was fully inhibited for up to 10 h at the 10 mg/kg dose. |